NAD+ · Research brief

5-Amino-1MQ Long Term Studies — Evidence & Safety Data

Real Peptides Research TeamEditorial

Updated July 9, 20267 min read

55 WORDS

Short answer

Most peptide compounds have decades of clinical observation. 5-amino-1MQ doesn't. The longest human trials tracked participants for 8–12 weeks. Not the multi-year timelines typical of approved metabolic therapies like metformin or GLP-1 agonists, which have been studied across 15+ year cohorts. Our team has worked with researchers evaluating novel peptides for metabolic health since 2018.

Key takeaways

The longest published human trial of 5-amino-1MQ lasted 84 days with 42 participants. No peer-reviewed study extends beyond 12 weeks.
NNMT inhibition theoretically affects methylation pathways, NAD+ metabolism, and hepatic enzyme regulation, but multi-year data showing how the body adapts across prolonged use doesn't exist.
Short-term trials showed 3.2kg mean fat mass reduction at 500mg daily without severe adverse events, though 18% of participants exhibited upward AST trends by week 10.
Post-discontinuation metabolic rebound has not been studied. We don't know if fat loss persists, stabilises, or reverses after stopping the compound.
Regulatory approval for metabolic therapies requires 52+ week trials with large cohorts. 5-amino-1MQ has completed Phase 1 safety assessment but lacks Phase 2 and Phase 3 data entirely.

Our team has worked with researchers evaluating novel peptides for metabolic health since 2018. The gap between preliminary efficacy data and genuine long-term safety evidence is wider for 5-amino-1MQ than for almost any other compound in active circulation today.

What is the current state of 5-amino-1MQ long term studies?

No peer-reviewed human trials of 5-amino-1MQ extend beyond 12 weeks of continuous administration. The compound inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular NAD+ metabolism and energy regulation. Short-term murine studies published in Cell Metabolism (2016) demonstrated fat mass reduction without caloric restriction, but human data remains confined to Phase 1 safety trials lasting 56–84 days. Without multi-year observation, questions about hepatic enzyme adaptation, methylation pathway disruption, and rebound metabolic effects remain unanswered.

The Evidence Gap That Defines 5-Amino-1MQ Research

Yes, there's preliminary data showing NNMT inhibition can shift cellular metabolism toward fat oxidation. But calling this 'long-term evidence' misrepresents the timeline. The longest published human trial of 5-amino-1MQ tracked 42 participants for 12 weeks, measuring body composition via DEXA and tracking liver enzyme panels weekly. That's not a long-term study by pharmacological standards. It's an extended Phase 1 safety window.

Long-term metabolic studies for approved therapies typically span 52 weeks minimum, with extension trials reaching 3–5 years. Semaglutide's STEP trials ran 68 weeks with 104-week extensions. Metformin has observational cohort data stretching across decades. For 5-amino-1MQ, we have 8–12 weeks. This article breaks down what those weeks revealed, what mechanisms remain uncharacterised, and what realistic safety concerns exist when the evidence timeline is this compressed.

What Existing 5-Amino-1MQ Long Term Studies Actually Measured

The 2016 murine study from Ulla Klingelhöfer's lab at the University of Copenhagen remains the foundational mechanistic work. Mice administered 5-amino-1MQ at 50mg/kg daily for 10 weeks showed 7% reduction in fat mass without corresponding decreases in food intake. Hepatic NNMT activity dropped by 72%, NAD+ levels increased by 38%, and mitochondrial oxidative capacity improved across visceral adipose tissue.

The human translation came later. A 2019 Phase 1 trial conducted at a registered clinical site in Arizona enrolled 42 adults (BMI 28–35) for 84 days of oral 5-amino-1MQ at escalating doses from 100mg to 500mg daily. Primary endpoints: liver enzyme stability (ALT, AST, GGT), renal function (creatinine, eGFR), and body composition changes via DEXA scan at weeks 0, 6, and 12. Results showed dose-dependent fat mass reduction (mean 3.2kg at 500mg dose) without statistically significant liver enzyme elevation, though AST crept upward in 18% of participants by week 10. Within normal range but trending.

That's the entire human evidence base for 5-amino-1MQ long term studies to date. No cardiovascular outcome trials. No cancer surveillance cohorts. No multi-year metabolic follow-up after discontinuation. The compound has been available through research suppliers since 2017, but no institution has published observational data beyond the 12-week threshold.

5-Amino-1MQ Long Term Studies: Mechanistic Concerns That Duration Data Would Address

NNMT inhibition doesn't operate in a vacuum. The enzyme sits at the intersection of methylation metabolism, NAD+ salvage, and one-carbon metabolism pathways. Blocking it long-term raises mechanistic questions that short trials can't answer.

First: methylation pathway disruption. NNMT converts nicotinamide to 1-methylnicotinamide using S-adenosylmethionine (SAM) as the methyl donor. Chronic inhibition theoretically spares SAM for other methylation reactions. DNA methylation, histone modification, neurotransmitter synthesis. But we don't have data showing how the body compensates across months or years. Does SAM accumulate? Do downstream methyltransferases upregulate to rebalance flux? Unknown.

Second: hepatic adaptation. The liver expresses NNMT at higher density than most tissues. Short-term trials showed transient AST elevation in a subset of users. Does that trend continue past week 12, stabilise, or resolve via enzyme adaptation? Metformin causes transient GI distress that resolves within 8 weeks as gut microbiome composition shifts. Similar adaptation could theoretically occur with 5-amino-1MQ, but there's no data confirming it.

Third: rebound metabolic effects. The 2019 Arizona trial didn't include a post-treatment follow-up arm. Participants stopped at week 12. Body composition wasn't reassessed at week 24 or 52. For context, GLP-1 agonist trials consistently show ~60% weight regain within one year of discontinuation. Does NNMT inhibition create similar rebound, or does the mitochondrial remodelling persist? We have no data.

5-Amino-1MQ Long Term Studies Comparison — What We Know vs What Approved Therapies Required

Here's what regulators demand versus what 5-amino-1MQ has delivered so far.

Regulatory Benchmark	FDA Approval Standard (Metabolic Therapies)	5-Amino-1MQ Evidence to Date	Gap Assessment
Phase 1 Safety	28–56 days, dose escalation, organ function monitoring	✓ Completed: 84-day trial in 42 adults	Met. Though small cohort
Phase 2 Efficacy	24–52 weeks, placebo-controlled, primary endpoint measurement	✗ No published trial >12 weeks	Missing entirely
Phase 3 Large Cohort	500+ participants, 52+ weeks, cardiovascular outcome tracking	✗ No trial initiated	Missing entirely
Long-Term Extension	2–5 years, cancer surveillance, organ function stability	✗ No observational data exists	Missing entirely
Post-Market Surveillance	Ongoing adverse event reporting, real-world outcomes	✗ Not applicable (research compound)	Not initiated

Approved metabolic therapies like liraglutide underwent 2,487-participant trials lasting 56 weeks before FDA clearance. Tirzepatide's SURMOUNT program enrolled 2,539 participants across 72-week trials. For 5-amino-1MQ long term studies, the total published human exposure is 42 people for 12 weeks. That's not a criticism of the compound's potential. It's a statement of where evidence development stands in 2026.

What If: 5-Amino-1MQ Long Term Studies Scenarios

What If I've Been Using 5-Amino-1MQ for Six Months — Is That Too Long?

There's no published human data past 12 weeks, so 'too long' can't be defined against a clinical benchmark. If you're monitoring liver enzymes (ALT, AST, GGT) quarterly and they remain stable, the absence of overt hepatotoxicity is reassuring. But it doesn't confirm long-term safety. NNMT inhibition's impact on methylation pathways and mitochondrial function across extended timelines hasn't been characterised. The prudent approach: periodic blood work every 8–12 weeks, including comprehensive metabolic panel and homocysteine as a methylation proxy.

What If I Stop Taking 5-Amino-1MQ — Will I Regain All the Fat I Lost?

No study has tracked post-treatment body composition, so this remains speculative. If the mechanism operates purely through acute NNMT inhibition (like how GLP-1 agonists require continuous receptor activation), fat regain would be expected. If mitochondrial remodelling persists after enzyme activity normalises, some benefit might remain. Our team's experience with metabolic peptides suggests partial regain is more common than full retention, but quantifying that for 5-amino-1MQ specifically requires post-treatment follow-up data that doesn't exist.

What If 5-Amino-1MQ Long Term Studies Eventually Show Liver Toxicity?

Short-term trials showed transient AST elevation in a minority of users, which resolved or stabilised by week 12. If extended observation reveals cumulative hepatotoxicity, the compound would follow the path of earlier PPAR agonists that showed promise in Phase 1 but failed Phase 2 due to organ stress. For compounds without FDA oversight, early adopters bear that risk directly. Which is why quarterly liver function monitoring isn't optional, it's the minimum viable harm-reduction protocol.

The Unflinching Truth About 5-Amino-1MQ Long Term Studies

Here's the honest answer: calling the existing evidence base 'long-term studies' is a mischaracterisation. Twelve weeks is an extended Phase 1 window. It's enough to rule out acute toxicity and confirm preliminary efficacy signals, but it's nowhere near the multi-year observation required to characterise cumulative risk, metabolic adaptation, or post-treatment rebound.

This doesn't mean 5-amino-1MQ is dangerous. It means we don't know yet. The murine data is compelling. The 84-day human trial showed fat loss without overt harm. But the absence of severe adverse events in 42 people over 12 weeks doesn't predict what happens in 4,200 people over 5 years. Metformin took two decades of real-world use before rare lactic acidosis risk was fully understood. Fen-phen passed Phase 1 and Phase 2 trials before valvular heart disease emerged in long-term users.

The gap between promising preliminary data and confident long-term safety assessment is real. If you're using 5-amino-1MQ in 2026, you're participating in the observational phase that formal trials haven't completed. That's a choice researchers and early adopters make with open eyes. Not because the compound is proven unsafe, but because it's not yet proven safe across the timelines that matter.

For those sourcing research peptides, quality and traceability become even more critical when long-term safety data is absent. Every batch of Real Peptides undergoes independent third-party purity verification through HPLC and mass spectrometry. A baseline standard that matters more when you're working with compounds where evidence development is still underway.

The timeline for genuine long-term human data on 5-amino-1MQ? Best case, 3–5 years if a Phase 2 trial launches soon. Realistically, longer. Until then, what we call 'long-term studies' are short-term trials with big mechanistic questions still unanswered.

Questions

The longest published human trial of 5-amino-1MQ followed participants for 84 days (12 weeks), not years. The 2019 Arizona Phase 1 study enrolled 42 adults at escalating doses from 100mg to 500mg daily, tracking liver enzymes, kidney function, and body composition. No peer-reviewed trial has extended observation beyond this 12-week threshold, which is typical for Phase 1 safety assessment but far shorter than the 52-week minimum standard for Phase 2 metabolic efficacy trials.

There’s no clinical evidence defining safe duration beyond 12 weeks because no study has tracked participants longer. If you choose extended use, quarterly monitoring of liver enzymes (ALT, AST, GGT), kidney function (creatinine, eGFR), and methylation markers like homocysteine becomes the minimum harm-reduction protocol. The absence of data doesn’t prove danger, but it also doesn’t confirm safety — you’re operating outside the characterised evidence window.

No published study includes post-treatment follow-up, so rebound effects remain uncharacterised. For context, GLP-1 agonist trials show ~60% weight regain within one year of stopping treatment. Whether 5-amino-1MQ creates similar rebound or whether mitochondrial adaptations persist after NNMT activity normalises is unknown — the Arizona trial ended at week 12 with no body composition reassessment at week 24 or 52.

Phase 1 trials prioritise acute safety — confirming a compound doesn’t cause immediate organ toxicity or severe adverse events. Longer Phase 2 and Phase 3 trials require significantly larger budgets, regulatory oversight, and institutional backing. Because 5-amino-1MQ remains a research compound without commercial pharmaceutical development, no entity has funded the multi-year trials that would generate genuine long-term safety and efficacy data.

NNMT inhibition affects methylation pathways (via SAM sparing), NAD+ salvage, and hepatic enzyme regulation — all systems where cumulative effects might not surface in 12 weeks. Potential concerns include chronic methylation pathway disruption, hepatic enzyme adaptation or stress, mitochondrial function changes that only manifest across months, and metabolic rebound after discontinuation. None of these have been ruled out because the observation window hasn’t extended long enough to detect them.

FDA-approved metabolic therapies like semaglutide (Wegovy) underwent 68-week Phase 3 trials with 2,000+ participants before approval, followed by ongoing post-market surveillance tracking adverse events across millions of prescriptions. Liraglutide has 15+ years of real-world observation. For 5-amino-1MQ, the total published human exposure is 42 participants for 12 weeks — it’s not a fair comparison because the compound hasn’t progressed through the regulatory pathway that generates multi-year safety data.

NNMT (nicotinamide N-methyltransferase) is an enzyme that converts nicotinamide to 1-methylnicotinamide using S-adenosylmethionine (SAM) as a methyl donor. Inhibiting it increases cellular NAD+ availability, which enhances mitochondrial fat oxidation. Long-term inhibition theoretically spares SAM for other methylation reactions (DNA methylation, neurotransmitter synthesis), but how the body compensates across months or years — whether SAM accumulates, whether other methyltransferases upregulate — hasn’t been studied in humans beyond 12 weeks.

Yes — quarterly at minimum. The 2019 trial tracked liver enzymes (ALT, AST, GGT), kidney function (creatinine, eGFR), and complete blood count weekly during the 12-week study. In the absence of long-term data, periodic monitoring is the only way to detect early organ stress or metabolic shifts. Adding homocysteine as a methylation pathway marker provides additional insight, since NNMT inhibition theoretically affects methyl donor metabolism.

Theoretically yes, but it would require a pharmaceutical entity to fund Phase 2 (52+ weeks, 200–500 participants) and Phase 3 (1,000+ participants, cardiovascular outcome tracking) trials. That process takes 5–8 years and costs hundreds of millions of dollars. Without patent protection (5-amino-1MQ’s core structure isn’t novel), no company has financial incentive to pursue FDA approval. It’s more likely to remain a research compound available through suppliers like Real Peptides unless a novel formulation or analogue becomes patentable.

The 2016 Cell Metabolism study by Klingelhöfer’s lab ran for 10 weeks in mice at 50mg/kg daily — showing 7% fat mass reduction, 72% drop in hepatic NNMT activity, and 38% increase in NAD+ without changes in food intake. Mice metabolise compounds faster than humans, and their lifespans compress timelines — 10 weeks in a mouse approximates months in human aging. The human trials used lower relative doses (100–500mg daily, roughly 1.4–7mg/kg in a 70kg adult) and shorter observation windows, making direct comparison difficult.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA